Literature DB >> 10229818

Tumor antigens are constitutively presented in the draining lymph nodes.

A L Marzo1, R A Lake, D Lo, L Sherman, A McWilliam, D Nelson, B W Robinson, B Scott.   

Abstract

Tumor growth is rarely associated with a strong specific CTL response, suggesting that the immune system is ignorant of the presence of tumor because the Ags are not readily available to or are sequestered from potential effector cells. We studied the in vivo activation of naive TCR transgenic hemagglutinin (HA)-specific CD8+ T cells adoptively transferred into mice bearing HA-expressing tumor using 5,6-carboxy-succinimidyl-fluorescein-ester labeling, which allows the identification of proliferating HA-specific T cells. We demonstrate that tumor Ags are constitutively presented in the lymph nodes draining tumors and are powerfully mitogenic for responding T cells despite the absence of anti-tumor CTL responses. Importantly, this proliferative signal occurs throughout tumor growth and is still detectable 6 mo after tumor inoculation when tumor is not palpable. These results provide the first evidence that there is constitutive presentation of tumor Ags in draining lymph nodes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229818

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

Authors:  Marieke F Fransen; Mark Schoonderwoerd; Philipp Knopf; Marcel Gm Camps; Lukas Jac Hawinkels; Manfred Kneilling; Thorbald van Hall; Ferry Ossendorp
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

Review 3.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

4.  The roles of antigen-specificity, responsiveness to transforming growth factor-β and antigen-presenting cell subsets in tumour-induced expansion of regulatory T cells.

Authors:  David Coe; Caroline Addey; Matthew White; Elizabeth Simpson; Julian Dyson; Jian-Guo Chai
Journal:  Immunology       Date:  2010-08-16       Impact factor: 7.397

5.  Lymph node biophysical remodeling is associated with melanoma lymphatic drainage.

Authors:  Nathan Andrew Rohner; Jacob McClain; Sara Lydia Tuell; Alex Warner; Blair Smith; Youngho Yun; Abhinav Mohan; Manuela Sushnitha; Susan Napier Thomas
Journal:  FASEB J       Date:  2015-07-15       Impact factor: 5.191

6.  Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.

Authors:  Aki Furusawa; John Reiser; Kavitha Sadashivaiah; Haley Simpson; Arnob Banerjee
Journal:  J Immunother       Date:  2018 Feb/Mar       Impact factor: 4.456

7.  TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.

Authors:  Tristan Courau; Djamel Nehar-Belaid; Laura Florez; Béatrice Levacher; Thomas Vazquez; Faustine Brimaud; Bertrand Bellier; David Klatzmann
Journal:  JCI Insight       Date:  2016-06-16

8.  Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells.

Authors:  A-S Bergot; A Durgeau; B Levacher; B M Colombo; J L Cohen; D Klatzmann
Journal:  Cancer Gene Ther       Date:  2010-05-14       Impact factor: 5.987

Review 9.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.